help button home button Endocrine Society JCEM ENDO 08
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Handelsman, D. J.
Right arrow Articles by Boylan, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Handelsman, D. J.
Right arrow Articles by Boylan, L. M.

Journal of Clinical Endocrinology & Metabolism, Vol 71, 216-222, Copyright © 1990 by Endocrine Society

ARTICLES

Pharmacokinetics and pharmacodynamics of testosterone pellets in man

DJ Handelsman, AJ Conway and LM Boylan
Andrology Unit, Royal Prince Alfred Hospital, Sydney, Australia.

We studied the pharmacokinetics and pharmacodynamics of sc implanted pellets of fused crystalline testosterone. Three different regimens (6 x 100 mg, 6 x 200 mg; and 3 x 200 mg) were compared in a prospective, cross-over clinical trial in which androgen deficient men were administered the three-dose combinations in a randomized starting order at intervals of at least 6 months. Plasma free and total testosterone, sex hormone-binding globulin, LH, and FSH were measured before and at monthly intervals for at least 6 months after 111 pellet implantation in 43 men with hypergonadotropic (n = 22) or hypogonadotropic (n = 21) hypogonadism. Total and free testosterone levels peaked at the first month and were maintained at physiological levels for 4 to 5 (600 mg doses) or 6 (1200 mg dose) months after a single implantation. Absorption of testosterone from 100 mg and 200 mg pellets closely approximated zero-order throughout the effective life of the pellets and exhibited a half-duration of 2.5 months. The estimated rate of release of testosterone was 1.5 (95% confidence limits 1.3-1.6) mg/day.200 mg pellet as determined from direct measurement of residue in pellets recovered after extrusion and confirmed independently from percent absorbed-time plots. The bioavailability of testosterone was virtually complete and the time course was predictable from the total implant dose and, to a lesser extent, total initial surface areas of pellets. Despite wide fluctuations in testosterone, SHBG levels were not changed during 6 months. In men with hypergonadotropic hypogonadism, both LH and FSH levels were uniformly and markedly suppressed by increased testosterone after pellet implants. LH and FSH were highly correlated with each other (r = 0.87) and inversely with total (r = 0.47 and 0.45, respectively) and free (r = 0.46 and 0.47) testosterone levels. Nadir LH levels occurred at 1-3 months (600 mg) and 1-4 months (1200 mg) reaching levels comparable with eugonadal controls. In contrast nadir FSH levels occurred at similar times but remained elevated compared with eugonadal controls. We conclude that fused pellets of crystalline testosterone provides very satisfactory depot androgen replacement exhibiting many desirable features for androgen replacement.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
P. Y. Liu, R. S. Swerdloff, B. D. Anawalt, R. A. Anderson, W. J. Bremner, J. Elliesen, Y.-Q. Gu, W. M. Kersemaekers, Robert. I. McLachlan, M. C. Meriggiola, et al.
Determinants of the Rate and Extent of Spermatogenic Suppression during Hormonal Male Contraception: An Integrated Analysis
J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1774 - 1783.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A.-M. Andersson, T. K. Jensen, A. Juul, J. H. Petersen, T. Jorgensen, and N. E. Skakkebaek
Secular Decline in Male Testosterone and Sex Hormone Binding Globulin Serum Levels in Danish Population Surveys
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4696 - 4705.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
K. L. Matthiesson and R. I. McLachlan
Male hormonal contraception: concept proven, product in sight?
Hum. Reprod. Update, July 1, 2006; 12(4): 463 - 482.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. Wu, Z. Wu, J. Yang, V. A. Nair, D. D. Miller, and J. T. Dalton
PHARMACOKINETICS AND METABOLISM OF A SELECTIVE ANDROGEN RECEPTOR MODULATOR IN RATS: IMPLICATION OF MOLECULAR PROPERTIES AND INTENSIVE METABOLIC PROFILE TO INVESTIGATE IDEAL PHARMACOKINETIC CHARACTERISTICS OF A PROPANAMIDE IN PRECLINICAL STUDY
Drug Metab. Dispos., March 1, 2006; 34(3): 483 - 494.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
M. Wald, R. B. Meacham, L. S. Ross, and C. S. Niederberger
Testosterone Replacement Therapy for Older Men
J Androl, March 1, 2006; 27(2): 126 - 132.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Wang, X. H. Wang, A. L. Nelson, K. K. Lee, Y. G. Cui, J. S. Tong, N. Berman, L. Lumbreras, A. Leung, L. Hull, et al.
Levonorgestrel Implants Enhanced the Suppression of Spermatogenesis by Testosterone Implants: Comparison between Chinese and Non-Chinese Men
J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 460 - 470.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
B.M. Brady, J.K. Amory, A. Perheentupa, M. Zitzmann, C.J. Hay, D. Apter, R.A. Anderson, W.J. Bremner, P. Pollanen, E. Nieschlag, et al.
A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive
Hum. Reprod., January 1, 2006; 21(1): 285 - 294.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Aminorroaya, S. Kelleher, A. J Conway, L. P Ly, and D. J Handelsman
Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men
Eur. J. Endocrinol., June 1, 2005; 152(6): 881 - 886.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
E. Nieschlag, H.M. Behre, P. Bouchard, J.J. Corrales, T.H. Jones, G.K. Stalla, S.M. Webb, and F.C.W. Wu
Testosterone replacement therapy: current trends and future directions
Hum. Reprod. Update, September 1, 2004; 10(5): 409 - 419.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Kelleher, A. J. Conway, and D. J. Handelsman
Blood Testosterone Threshold for Androgen Deficiency Symptoms
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3813 - 3817.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Meier, P. Y. Liu, L. P. Ly, J. de Winter-Modzelewski, M. Jimenez, D. J. Handelsman, and M. J. Seibel
Recombinant Human Chorionic Gonadotropin But Not Dihydrotestosterone Alone Stimulates Osteoblastic Collagen Synthesis in Older Men with Partial Age-Related Androgen Deficiency
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 3033 - 3041.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. W. F. T. Toorians, S. Kelleher, L. J. Gooren, M. Jimenez, and D. J. Handelsman
Estimating the Contribution of the Prostate to Blood Dihydrotestosterone
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5207 - 5211.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. Turner, A. J. Conway, M. Jimenez, P. Y. Liu, E. Forbes, R. I. McLachlan, and D. J. Handelsman
Contraceptive Efficacy of a Depot Progestin and Androgen Combination in Men
J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4659 - 4667.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Yin, H. Xu, Y. He, L. I. Kirkovsky, D. D. Miller, and J. T. Dalton
Pharmacology, Pharmacokinetics, and Metabolism of Acetothiolutamide, a Novel Nonsteroidal Agonist for the Androgen Receptor
J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1323 - 1333.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Yin, W. Gao, J. D. Kearbey, H. Xu, K. Chung, Y. He, C. A. Marhefka, K. A. Veverka, D. D. Miller, and J. T. Dalton
Pharmacodynamics of Selective Androgen Receptor Modulators
J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1334 - 1340.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Y. Liu, S. M. Wishart, and D. J. Handelsman
A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Recombinant Human Chorionic Gonadotropin on Muscle Strength and Physical Function and Activity in Older Men with Partial Age-Related Androgen Deficiency
J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3125 - 3135.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. P. Ly, M. Jimenez, T. N. Zhuang, D. S. Celermajer, A. J. Conway, and D. J. Handelsman
A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Transdermal Dihydrotestosterone Gel on Muscular Strength, Mobility, and Quality of Life in Older Men with Partial Androgen Deficiency
J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4078 - 4088.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
C. W. Martin, S. C. Riley, D. Everington, N. P. Groome, R. A. Riemersma, D. T. Baird, and R. A. Anderson
Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary-testicular axis in normal men
Hum. Reprod., July 1, 2000; 15(7): 1515 - 1524.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
D. J. Handelsman, S. Wishart, and A. J. Conway
Oestradiol enhances testosterone-induced suppression of human spermatogenesis
Hum. Reprod., March 1, 2000; 15(3): 672 - 679.
[Abstract] [Full Text] [PDF]

Home page
 Arch Fam MedHome page
S. J. Winters
Current Status of Testosterone Replacement Therapy in Men
Arch Fam Med, May 1, 1999; 8(3): 257 - 263.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. M. Buckler, W. R. Robertson, and F. C. W. Wu
Which Androgen Replacement Therapy for Women?
J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3920 - 3924.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. S. Dobs, D. R. Hoover, M.-C. Chen, and R. Allen
Pharmacokinetic Characteristics, Efficacy, and Safety of Buccal Testosterone in Hypogonadal Males: A Pilot Study
J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 33 - 39.
[Abstract] [Full Text]

Home page
 Arch. Dis. Child.Home page
M R Zacharin and G L Warne
Treatment of hypogonadal adolescent boys with long acting subcutaneous testosterone pellets
Arch. Dis. Child., June 1, 1997; 76(6): 495 - 499.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Bhasin and W. J. Bremner
Emerging Issues in Androgen Replacement Therapy
J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 3 - 8.
[Full Text] [PDF]

Home page
 NEJMHome page
C. J. Bagatell and W. J. Bremner
Androgens in Men -- Uses and Abuses
N. Engl. J. Med., March 14, 1996; 334(11): 707 - 715.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society